Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.50 |
| ▸ | FABP7 | O15540 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14947096 | 0.88 | KMT2A (0.52) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL1940665 | 0.88 | KMT2A (0.52) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL97613 | 0.86 | KMT2A (0.50) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL9660107 | 0.85 | CYP1A2 (0.53) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL31756603 | 0.85 | CYP1A2 (0.53) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL1829602 | 0.85 | FABP5 (0.50) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL1829604 | 0.85 | FABP5 (0.50) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL25144 | 0.85 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL524545 | 0.84 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL3976225 | 0.84 | KMT2A (0.48) | KMT2AFABP5FABP7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106661084-B | Macrocyclic broad spectrum antibiotics | 阿奇克斯制药公司 | 2021-08-31 | — | — | CN | disclosed |
| EP-3145944-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3085388-B1 | HYPERBRANCHED POLYMER CONJUGATES VIA NON-ENZYMATIC CLEAVABLE LINKER | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2021-04-07 | — | — | EP | disclosed |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-10351595-B2 | — | — | 2019-07-16 | — | — | US | disclosed |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| EP-3145944-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-9512139-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2016-12-06 | — | — | US | disclosed |
| EP-3085388-A1 | HYPERBRANCHED POLYMER CONJUGATES VIA NON-ENZYMATIC CLEAVABLE LINKER | Ascendis Pharma Growth Disorders Division A/S (DK) | 2016-10-26 | — | — | EP | disclosed |
| US-6875760-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-04-05 | — | — | US | disclosed |
| EP-1379881-B1 | METHOD FOR DETERMINING THE SUBSTRATE SPECIFICITY OF AN ENZYMATIC ACTIVITY AND A DEVICE THEREFOR | JERINI AG (DE) | 2004-10-06 | — | — | EP | disclosed |
| EP-1379881-A2 | METHOD FOR DETERMINING THE SUBSTRATE SPECIFICITY OF AN ENZYMATIC ACTIVITY AND A DEVICE THEREFOR | Jerini AG (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-6660832-B1 | Cyclic peptide compounds with fused benzene rings; solid phase synthesis thereof; use as antibiotic to treat bacterial infection in mammals; may work by binding to RNA targets | ISIS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2003-11-27 | — | — | US | disclosed |
| US-6503949-B1 | Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity | NORO NORDISK A/S (DK) | 2003-01-07 | — | — | US | disclosed |
| WO-2002083933-A2 | METHOD FOR DETERMINING THE SUBSTRATE SPECIFICITY OF AN ENZYMATIC ACTIVITY AND A DEVICE THEREFOR | JERINI AG (DE) | 2002-10-24 | — | — | WO | disclosed |
| EP-1183229-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| WO-2001014346-A1 | MACROCYCLIC COMPOUNDS AND PREPARATION METHODS THEREOF | ISIS PHARMACEUTICALS, INC. (US) | 2001-03-01 | — | — | WO | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351595-B2 | — | MRPL21, PRSS1, PEPD | KMT2A 4084/4885FABP5 2014/4885FABP7 3202/4885 |
| US-10392422-B2 | Macrocyclic broad spectrum antibiotics | MRPL21, PEPD, CTSC | KMT2A 3283/4885FABP5 3094/4885FABP7 4034/4885 |
| US-20030220350-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | KMT2A 3304/4885FABP5 1237/4885FABP7 952/4885 |
| US-20170088582-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | KMT2A 3283/4885FABP5 3094/4885FABP7 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.